Risks associated with potential predictors of endoscopic/surgical relapse after the first endoscopic dilation
| OR | 95% CI | p-Value† | |
| Endoscopy (i2–i4) | 1.257 | 0.637 to 2.459 | 0.857 |
| CRP (>5 mg/l) | 1.033 | 0.753 to 1.418 | 0.976 |
| Sex (female) | 1.072 | 0.546 to 2.104 | 0.835 |
| Age (>49 years)* | 1.061 | 0.762 to 1.477 | 0.29 |
| Duration of disease (>17 years) | 0.707 | 0.354 to 1.389 | 0.131 |
| Therapy after dilation | |||
| 5-ASA | 1.994 | 0.953 to 4.170 | 0.526 |
| Budesonide | 1.164 | 0.510 to 2.653 | 0.204 |
| Anti-TNF | 0.561 | 0.213 to 1.494 | 0.78 |
| Antimetabolites | 0.651 | 0.313 to 1.355 | 0.285 |
| No therapy | 0.805 | 0.317 to 2.043 | 0.227 |
↵* Age and duration of disease patients were classified according to the median value in the total population. In the Kaplan–Meier and Cox regression analysis patients with a value above the median were separated from those with a value below median.
↵† p Values are derived from a Cox forward conditional proportional hazards regression analysis.
5-ASA, 5-aminosalicylic acid; CRP, C-reactive protein; TNF, tumour necrosis factor.